Consensus-based guideline of the Korean Society of Gynecologic Oncology for high-risk human papillomavirus testing in cervical cancer screening.

High-risk human papillomavirus (hrHPV) is an important cause of cervical cancer. hrHPV testing has emerged as an effective screening modality to address the limitations of cytology-based screening. However, in Korea, the absence of standardized clinical guidance has resulted in variability in practice. This consensus-based clinical practice guideline was developed by a multidisciplinary expert committee under the Korean Society of Gynecologic Oncology and includes specialists in gynecologic oncology, pathology, laboratory medicine, and public health. Relevant domestic and international evidence was systematically reviewed and perspectives from diverse clinical settings were incorporated through four public hearings. The final recommendations were established through expert consensus. These guidelines present four key recommendations. First, hrHPV testing may be considered for women aged ≥25 years, with a screening interval of 3 to <5 years. Second, screening assays should differentiate between HPV genotypes 16 and 18 while detecting other high-risk types, and tests with established clinical validity are recommended. Third, hrHPV testing should be performed in appropriately equipped settings, following standardized procedures for specimen handling and reporting, with clear documentation of HPV 16/18 status in positive cases. Fourth, the testing should operate under rigorous internal and external quality control systems to ensure reliability and consistency. These guidelines aim to promote consistent and evidence-based implementation of hrHPV testing for cervical cancer screening in Korea, supporting early detection and prevention.